Serveur d'exploration sur les récepteurs immunitaires végétaux

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Narciclasine improves outcome in sepsis among neonatal rats via inhibition of calprotectin and alleviating inflammatory responses.

Identifieur interne : 000103 ( Main/Exploration ); précédent : 000102; suivant : 000104

Narciclasine improves outcome in sepsis among neonatal rats via inhibition of calprotectin and alleviating inflammatory responses.

Auteurs : Manoj Kumar Kingsley [Inde] ; Ballambattu Vishnu Bhat [Inde] ; Bhawana Ashok Badhe [Inde] ; Benet Bosco Dhas [Inde] ; Subhash Chandra Parija [Inde]

Source :

RBID : pubmed:32076015

Descripteurs français

English descriptors

Abstract

Sepsis is associated with exacerbated inflammatory response which subsequently results in multiple organ dysfunction. Sepsis accounts for high mortality and morbidity among newborns worldwide. Narciclasine is a plant alkaloid which has shown to possess anti-inflammatory properties. In this study we investigated the effect and mechanism of action of narciclasine in neonatal sepsis rat models. The excessive release of S100A8/A9 or calprotectin in neonatal sepsis could be detrimental as it could exacerbate the inflammatory responses. We found that narciclasine significantly reduced the plasma levels of S100A8/A9 and also suppressed its expression in the liver and lung. The systemic and local bacterial load was also reduced in the narciclasine treated rats. The systemic and local production of pro-inflammatory cytokines in plasma and organs (liver and lungs) was significantly reduced in the narciclasine treated rats. The histopathological studies showed that narciclasine prevents the organ damage associated with sepsis and improved the survival of neonatal rats. Sepsis increased the phosphorylated NF-κβ p65 protein expression in the liver. Narciclasine suppressed the phosphorylation of NF-κβ p65 and the degradation of NF-κβ inhibitory protein alpha. It could also suppress the expression of adaptor proteins of the toll like receptor signaling pathway viz., myeloid differentiation factor 88 (MyD88), Interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6). These results suggest that narciclasine protects against sepsis in neonatal rats through the inhibition of calprotectin, pro-inflammatory cytokines and suppression of NF-κβ signaling pathway.

DOI: 10.1038/s41598-020-59716-7
PubMed: 32076015
PubMed Central: PMC7031385


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Narciclasine improves outcome in sepsis among neonatal rats via inhibition of calprotectin and alleviating inflammatory responses.</title>
<author>
<name sortKey="Kingsley, Manoj Kumar" sort="Kingsley, Manoj Kumar" uniqKey="Kingsley M" first="Manoj Kumar" last="Kingsley">Manoj Kumar Kingsley</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neonatology, JIPMER, Puducherry, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Department of Neonatology, JIPMER, Puducherry</wicri:regionArea>
<wicri:noRegion>Puducherry</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Bhat, Ballambattu Vishnu" sort="Bhat, Ballambattu Vishnu" uniqKey="Bhat B" first="Ballambattu Vishnu" last="Bhat">Ballambattu Vishnu Bhat</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neonatology, JIPMER, Puducherry, India. drvishnubhat@yahoo.com.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Department of Neonatology, JIPMER, Puducherry</wicri:regionArea>
<wicri:noRegion>Puducherry</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Badhe, Bhawana Ashok" sort="Badhe, Bhawana Ashok" uniqKey="Badhe B" first="Bhawana Ashok" last="Badhe">Bhawana Ashok Badhe</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Pathology, JIPMER, Puducherry, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Department of Pathology, JIPMER, Puducherry</wicri:regionArea>
<wicri:noRegion>Puducherry</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Dhas, Benet Bosco" sort="Dhas, Benet Bosco" uniqKey="Dhas B" first="Benet Bosco" last="Dhas">Benet Bosco Dhas</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neonatology, JIPMER, Puducherry, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Department of Neonatology, JIPMER, Puducherry</wicri:regionArea>
<wicri:noRegion>Puducherry</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Parija, Subhash Chandra" sort="Parija, Subhash Chandra" uniqKey="Parija S" first="Subhash Chandra" last="Parija">Subhash Chandra Parija</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Microbiology, JIPMER, Puducherry, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Department of Microbiology, JIPMER, Puducherry</wicri:regionArea>
<wicri:noRegion>Puducherry</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32076015</idno>
<idno type="pmid">32076015</idno>
<idno type="doi">10.1038/s41598-020-59716-7</idno>
<idno type="pmc">PMC7031385</idno>
<idno type="wicri:Area/Main/Corpus">000208</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000208</idno>
<idno type="wicri:Area/Main/Curation">000208</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000208</idno>
<idno type="wicri:Area/Main/Exploration">000208</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Narciclasine improves outcome in sepsis among neonatal rats via inhibition of calprotectin and alleviating inflammatory responses.</title>
<author>
<name sortKey="Kingsley, Manoj Kumar" sort="Kingsley, Manoj Kumar" uniqKey="Kingsley M" first="Manoj Kumar" last="Kingsley">Manoj Kumar Kingsley</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neonatology, JIPMER, Puducherry, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Department of Neonatology, JIPMER, Puducherry</wicri:regionArea>
<wicri:noRegion>Puducherry</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Bhat, Ballambattu Vishnu" sort="Bhat, Ballambattu Vishnu" uniqKey="Bhat B" first="Ballambattu Vishnu" last="Bhat">Ballambattu Vishnu Bhat</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neonatology, JIPMER, Puducherry, India. drvishnubhat@yahoo.com.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Department of Neonatology, JIPMER, Puducherry</wicri:regionArea>
<wicri:noRegion>Puducherry</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Badhe, Bhawana Ashok" sort="Badhe, Bhawana Ashok" uniqKey="Badhe B" first="Bhawana Ashok" last="Badhe">Bhawana Ashok Badhe</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Pathology, JIPMER, Puducherry, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Department of Pathology, JIPMER, Puducherry</wicri:regionArea>
<wicri:noRegion>Puducherry</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Dhas, Benet Bosco" sort="Dhas, Benet Bosco" uniqKey="Dhas B" first="Benet Bosco" last="Dhas">Benet Bosco Dhas</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neonatology, JIPMER, Puducherry, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Department of Neonatology, JIPMER, Puducherry</wicri:regionArea>
<wicri:noRegion>Puducherry</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Parija, Subhash Chandra" sort="Parija, Subhash Chandra" uniqKey="Parija S" first="Subhash Chandra" last="Parija">Subhash Chandra Parija</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Microbiology, JIPMER, Puducherry, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Department of Microbiology, JIPMER, Puducherry</wicri:regionArea>
<wicri:noRegion>Puducherry</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Scientific reports</title>
<idno type="eISSN">2045-2322</idno>
<imprint>
<date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Acute Lung Injury (blood)</term>
<term>Acute Lung Injury (drug therapy)</term>
<term>Acute Lung Injury (pathology)</term>
<term>Amaryllidaceae Alkaloids (pharmacology)</term>
<term>Amaryllidaceae Alkaloids (therapeutic use)</term>
<term>Anemia (complications)</term>
<term>Animals (MeSH)</term>
<term>Animals, Newborn (MeSH)</term>
<term>Bacterial Load (MeSH)</term>
<term>Inflammation (blood)</term>
<term>Inflammation (complications)</term>
<term>Inflammation (drug therapy)</term>
<term>Inflammation (pathology)</term>
<term>Inflammation Mediators (blood)</term>
<term>Interleukin-6 (metabolism)</term>
<term>Leukocyte L1 Antigen Complex (metabolism)</term>
<term>Liver (injuries)</term>
<term>Liver (pathology)</term>
<term>Phenanthridines (pharmacology)</term>
<term>Phenanthridines (therapeutic use)</term>
<term>Phosphorylation (drug effects)</term>
<term>Rats (MeSH)</term>
<term>S100 Proteins (blood)</term>
<term>S100 Proteins (metabolism)</term>
<term>Sepsis (blood)</term>
<term>Sepsis (complications)</term>
<term>Sepsis (drug therapy)</term>
<term>Sepsis (microbiology)</term>
<term>Signal Transduction (drug effects)</term>
<term>Survival Analysis (MeSH)</term>
<term>Toll-Like Receptor 4 (metabolism)</term>
<term>Transcription Factor RelA (metabolism)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Tumor Necrosis Factor-alpha (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Alcaloïdes des Amaryllidaceae (pharmacologie)</term>
<term>Alcaloïdes des Amaryllidaceae (usage thérapeutique)</term>
<term>Analyse de survie (MeSH)</term>
<term>Animaux (MeSH)</term>
<term>Animaux nouveau-nés (MeSH)</term>
<term>Anémie (complications)</term>
<term>Charge bactérienne (MeSH)</term>
<term>Complexe antigénique L1 leucocytaire (métabolisme)</term>
<term>Facteur de nécrose tumorale alpha (métabolisme)</term>
<term>Facteur de transcription RelA (métabolisme)</term>
<term>Foie (anatomopathologie)</term>
<term>Foie (traumatismes)</term>
<term>Inflammation (anatomopathologie)</term>
<term>Inflammation (complications)</term>
<term>Inflammation (sang)</term>
<term>Inflammation (traitement médicamenteux)</term>
<term>Interleukine-6 (métabolisme)</term>
<term>Lésion pulmonaire aigüe (anatomopathologie)</term>
<term>Lésion pulmonaire aigüe (sang)</term>
<term>Lésion pulmonaire aigüe (traitement médicamenteux)</term>
<term>Médiateurs de l'inflammation (sang)</term>
<term>Phosphorylation (effets des médicaments et des substances chimiques)</term>
<term>Phénanthridines (pharmacologie)</term>
<term>Phénanthridines (usage thérapeutique)</term>
<term>Protéines S100 (métabolisme)</term>
<term>Protéines S100 (sang)</term>
<term>Rats (MeSH)</term>
<term>Récepteur de type Toll-4 (métabolisme)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Sepsie (complications)</term>
<term>Sepsie (microbiologie)</term>
<term>Sepsie (sang)</term>
<term>Sepsie (traitement médicamenteux)</term>
<term>Transduction du signal (effets des médicaments et des substances chimiques)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Inflammation Mediators</term>
<term>S100 Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Interleukin-6</term>
<term>Leukocyte L1 Antigen Complex</term>
<term>S100 Proteins</term>
<term>Toll-Like Receptor 4</term>
<term>Transcription Factor RelA</term>
<term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Amaryllidaceae Alkaloids</term>
<term>Phenanthridines</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Foie</term>
<term>Inflammation</term>
<term>Lésion pulmonaire aigüe</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en">
<term>Acute Lung Injury</term>
<term>Inflammation</term>
<term>Sepsis</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Anemia</term>
<term>Inflammation</term>
<term>Sepsis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Phosphorylation</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Acute Lung Injury</term>
<term>Inflammation</term>
<term>Sepsis</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Phosphorylation</term>
<term>Transduction du signal</term>
</keywords>
<keywords scheme="MESH" qualifier="injuries" xml:lang="en">
<term>Liver</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr">
<term>Sepsie</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiology" xml:lang="en">
<term>Sepsis</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Anémie</term>
<term>Complexe antigénique L1 leucocytaire</term>
<term>Facteur de nécrose tumorale alpha</term>
<term>Facteur de transcription RelA</term>
<term>Inflammation</term>
<term>Interleukine-6</term>
<term>Protéines S100</term>
<term>Récepteur de type Toll-4</term>
<term>Sepsie</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Acute Lung Injury</term>
<term>Inflammation</term>
<term>Liver</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Alcaloïdes des Amaryllidaceae</term>
<term>Phénanthridines</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Inflammation</term>
<term>Lésion pulmonaire aigüe</term>
<term>Médiateurs de l'inflammation</term>
<term>Protéines S100</term>
<term>Sepsie</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Amaryllidaceae Alkaloids</term>
<term>Phenanthridines</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Inflammation</term>
<term>Lésion pulmonaire aigüe</term>
<term>Sepsie</term>
</keywords>
<keywords scheme="MESH" qualifier="traumatismes" xml:lang="fr">
<term>Foie</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Alcaloïdes des Amaryllidaceae</term>
<term>Phénanthridines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Animals, Newborn</term>
<term>Bacterial Load</term>
<term>Rats</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Analyse de survie</term>
<term>Animaux</term>
<term>Animaux nouveau-nés</term>
<term>Charge bactérienne</term>
<term>Rats</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Sepsis is associated with exacerbated inflammatory response which subsequently results in multiple organ dysfunction. Sepsis accounts for high mortality and morbidity among newborns worldwide. Narciclasine is a plant alkaloid which has shown to possess anti-inflammatory properties. In this study we investigated the effect and mechanism of action of narciclasine in neonatal sepsis rat models. The excessive release of S100A8/A9 or calprotectin in neonatal sepsis could be detrimental as it could exacerbate the inflammatory responses. We found that narciclasine significantly reduced the plasma levels of S100A8/A9 and also suppressed its expression in the liver and lung. The systemic and local bacterial load was also reduced in the narciclasine treated rats. The systemic and local production of pro-inflammatory cytokines in plasma and organs (liver and lungs) was significantly reduced in the narciclasine treated rats. The histopathological studies showed that narciclasine prevents the organ damage associated with sepsis and improved the survival of neonatal rats. Sepsis increased the phosphorylated NF-κβ p65 protein expression in the liver. Narciclasine suppressed the phosphorylation of NF-κβ p65 and the degradation of NF-κβ inhibitory protein alpha. It could also suppress the expression of adaptor proteins of the toll like receptor signaling pathway viz., myeloid differentiation factor 88 (MyD88), Interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6). These results suggest that narciclasine protects against sepsis in neonatal rats through the inhibition of calprotectin, pro-inflammatory cytokines and suppression of NF-κβ signaling pathway.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">32076015</PMID>
<DateCompleted>
<Year>2020</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2020</Year>
<Month>11</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">2045-2322</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>10</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2020</Year>
<Month>02</Month>
<Day>19</Day>
</PubDate>
</JournalIssue>
<Title>Scientific reports</Title>
<ISOAbbreviation>Sci Rep</ISOAbbreviation>
</Journal>
<ArticleTitle>Narciclasine improves outcome in sepsis among neonatal rats via inhibition of calprotectin and alleviating inflammatory responses.</ArticleTitle>
<Pagination>
<MedlinePgn>2947</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-59716-7</ELocationID>
<Abstract>
<AbstractText>Sepsis is associated with exacerbated inflammatory response which subsequently results in multiple organ dysfunction. Sepsis accounts for high mortality and morbidity among newborns worldwide. Narciclasine is a plant alkaloid which has shown to possess anti-inflammatory properties. In this study we investigated the effect and mechanism of action of narciclasine in neonatal sepsis rat models. The excessive release of S100A8/A9 or calprotectin in neonatal sepsis could be detrimental as it could exacerbate the inflammatory responses. We found that narciclasine significantly reduced the plasma levels of S100A8/A9 and also suppressed its expression in the liver and lung. The systemic and local bacterial load was also reduced in the narciclasine treated rats. The systemic and local production of pro-inflammatory cytokines in plasma and organs (liver and lungs) was significantly reduced in the narciclasine treated rats. The histopathological studies showed that narciclasine prevents the organ damage associated with sepsis and improved the survival of neonatal rats. Sepsis increased the phosphorylated NF-κβ p65 protein expression in the liver. Narciclasine suppressed the phosphorylation of NF-κβ p65 and the degradation of NF-κβ inhibitory protein alpha. It could also suppress the expression of adaptor proteins of the toll like receptor signaling pathway viz., myeloid differentiation factor 88 (MyD88), Interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6). These results suggest that narciclasine protects against sepsis in neonatal rats through the inhibition of calprotectin, pro-inflammatory cytokines and suppression of NF-κβ signaling pathway.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kingsley</LastName>
<ForeName>Manoj Kumar</ForeName>
<Initials>MK</Initials>
<AffiliationInfo>
<Affiliation>Department of Neonatology, JIPMER, Puducherry, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bhat</LastName>
<ForeName>Ballambattu Vishnu</ForeName>
<Initials>BV</Initials>
<AffiliationInfo>
<Affiliation>Department of Neonatology, JIPMER, Puducherry, India. drvishnubhat@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Badhe</LastName>
<ForeName>Bhawana Ashok</ForeName>
<Initials>BA</Initials>
<AffiliationInfo>
<Affiliation>Department of Pathology, JIPMER, Puducherry, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dhas</LastName>
<ForeName>Benet Bosco</ForeName>
<Initials>BB</Initials>
<AffiliationInfo>
<Affiliation>Department of Neonatology, JIPMER, Puducherry, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Parija</LastName>
<ForeName>Subhash Chandra</ForeName>
<Initials>SC</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology, JIPMER, Puducherry, India.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2020</Year>
<Month>02</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Sci Rep</MedlineTA>
<NlmUniqueID>101563288</NlmUniqueID>
<ISSNLinking>2045-2322</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047151">Amaryllidaceae Alkaloids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039841">Leukocyte L1 Antigen Complex</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010617">Phenanthridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009418">S100 Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051996">Transcription Factor RelA</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>29477-83-6</RegistryNumber>
<NameOfSubstance UI="C010753">narciclasine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D055371" MajorTopicYN="N">Acute Lung Injury</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D047151" MajorTopicYN="N">Amaryllidaceae Alkaloids</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000740" MajorTopicYN="N">Anemia</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058491" MajorTopicYN="N">Bacterial Load</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D039841" MajorTopicYN="N">Leukocyte L1 Antigen Complex</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
<QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010617" MajorTopicYN="N">Phenanthridines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009418" MajorTopicYN="N">S100 Proteins</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051996" MajorTopicYN="N">Transcription Factor RelA</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2019</Year>
<Month>02</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2020</Year>
<Month>02</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2020</Year>
<Month>2</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2020</Year>
<Month>2</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2020</Year>
<Month>11</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">32076015</ArticleId>
<ArticleId IdType="doi">10.1038/s41598-020-59716-7</ArticleId>
<ArticleId IdType="pii">10.1038/s41598-020-59716-7</ArticleId>
<ArticleId IdType="pmc">PMC7031385</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Chem Rev. 2008 Jun;108(6):1982-2014</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18489166</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Pharm Bull. 1999 Jul;22(7):674-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10443460</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Care Med. 2001 Jul;29(7):1303-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11445675</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Drug Targets Infect Disord. 2001 Aug;1(2):91-106</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12455407</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Physiol Lung Cell Mol Physiol. 2006 Apr;290(4):L622-L645</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16531564</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2003 May 15;101(10):3765-77</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12543869</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Prev Med. 2011 Oct;2(4):238-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22174963</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Leukoc Biol. 1997 Jan;61(1):50-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9000536</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Microbiol Rev. 2014 Jan;27(1):21-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24396135</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pediatr Clin North Am. 2004 Aug;51(4):939-59, viii-ix</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15275982</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Ethnopharmacol. 1999 Nov 30;67(3):327-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10617068</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Sci Rep. 2018 Jul 25;8(1):11198</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">30046137</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 1990 Sep 29;336(8718):763-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1976144</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Dev Immunol. 2008;2008:628963</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18825269</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect Dis. 2003 Jun 15;187 Suppl 2:S364-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12792853</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Nat Prod. 2012 Mar 23;75(3):311-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22316239</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Neurol. 2011 Feb;69(2):341-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21387379</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol Res. 2017;2017:8601063</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">28367457</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Vaccines (Basel). 2017 Oct 04;5(4):</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">28976923</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neoplasia. 2007 Sep;9(9):766-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17898872</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Leukoc Biol. 2009 Sep;86(3):557-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19451397</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Host Microbe. 2011 Aug 18;10(2):158-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21843872</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Leukoc Biol. 1995 Dec;58(6):650-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7499962</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Infect Immun. 2003 Aug;71(8):4711-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12874352</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS Pathog. 2012;8(10):e1002987</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23133376</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Med Chem. 2009 Feb 26;52(4):1100-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19199649</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Ethnopharmacol. 2008 Oct 28;119(3):331-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18703129</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Vis Exp. 2012 Apr 11;(62):</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22525208</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2002 Nov 1;169(9):5209-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12391239</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Mol Med. 2015 May;19(5):1021-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25754537</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Antimicrob Agents Chemother. 2011 Jul;55(7):3567-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21502635</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Dev Immunol. 2011;2011:291085</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21765851</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Med. 2007 Sep;13(9):1042-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17767165</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virulence. 2014 Jan 1;5(1):4-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24335434</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Microbiol Immunol. 2011 Oct;55(10):736-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21831206</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Life Sci. 2000 Dec 8;68(3):241-58</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11191641</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Adv Pharmacol Sci. 2011;2011:254619</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21738527</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Acta Paediatr. 2003;92(2):221-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12710650</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genomics. 1995 Feb 10;25(3):638-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7759097</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol Res. 2015;2015:147973</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26380313</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Microbiol Rev. 1993 Jan;6(1):57-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8457980</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Care. 2009;13(5):R150</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19758459</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pediatrics. 2011 May;127(5):817-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21518717</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Drug Discov. 2005 Mar;4(3):206-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15729362</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Physiol Lung Cell Mol Physiol. 2012 Sep;303(5):L355-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22707617</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Care Med. 2009 Aug;37(8):2448-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19531940</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Physiol Res. 2004;53(3):245-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15209531</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Care Med. 2001 Jul;29(7 Suppl):S42-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11445733</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2005 Apr 1;105(7):2955-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15598812</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Transl Oncol. 2008 Mar;1(1):1-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18607503</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):E6390-E6399</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">28720697</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mediators Inflamm. 2013;2013:361501</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24324295</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2006 Jul 8;368(9530):157-69</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16829300</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Med Hypotheses. 2014 Mar;82(3):382-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24495564</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int Rev Immunol. 2014 Nov-Dec;33(6):498-510</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24611785</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Med. 2016 May;21(1):951-958</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26736178</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Pharm Bull. 2003 Jun;26(6):753-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12808281</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virulence. 2014 Jan 1;5(1):170-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24185532</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Inde</li>
</country>
</list>
<tree>
<country name="Inde">
<noRegion>
<name sortKey="Kingsley, Manoj Kumar" sort="Kingsley, Manoj Kumar" uniqKey="Kingsley M" first="Manoj Kumar" last="Kingsley">Manoj Kumar Kingsley</name>
</noRegion>
<name sortKey="Badhe, Bhawana Ashok" sort="Badhe, Bhawana Ashok" uniqKey="Badhe B" first="Bhawana Ashok" last="Badhe">Bhawana Ashok Badhe</name>
<name sortKey="Bhat, Ballambattu Vishnu" sort="Bhat, Ballambattu Vishnu" uniqKey="Bhat B" first="Ballambattu Vishnu" last="Bhat">Ballambattu Vishnu Bhat</name>
<name sortKey="Dhas, Benet Bosco" sort="Dhas, Benet Bosco" uniqKey="Dhas B" first="Benet Bosco" last="Dhas">Benet Bosco Dhas</name>
<name sortKey="Parija, Subhash Chandra" sort="Parija, Subhash Chandra" uniqKey="Parija S" first="Subhash Chandra" last="Parija">Subhash Chandra Parija</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PlantImRecepV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000103 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000103 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    PlantImRecepV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32076015
   |texte=   Narciclasine improves outcome in sepsis among neonatal rats via inhibition of calprotectin and alleviating inflammatory responses.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32076015" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a PlantImRecepV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat Nov 21 12:33:18 2020. Site generation: Sat Nov 21 12:33:47 2020